Anna Kan

6PUBLICATIONS
18CO-AUTHORS
Haematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Dec 08, 2025
HBV Reactivation in Patients with Hepatocellular Carcinoma Treated with PD-1/-L1 Antibodies and Concurrent Antiviral Prophylaxis Agents: A Prospective Observational Study.

Zefeng Du, Zhicheng Lai, Yexing Huang

|Jul 16, 2024
UBA2 SUMOylates NQO1 and promotes the proliferation of hepatocellular carcinoma by modulating the MAPK pathway.

Hailong Chen, Huifang Li, Minke He

|Nov 25, 2023
DNA methylation-activated full-length EMX1 facilitates metastasis through EMX1-EGFR-ERK axis in hepatocellular carcinoma.

Dong-Sheng Wen, Li-Chang Huang, Xiao-Yun Bu

|Oct 11, 2023
Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC).

MinKe He, YeXing Huang, ZeFeng Du

|Dec 19, 2022
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials.

YeXing Huang, LiHong Zhang, MinKe He

|Jun 25, 2021
Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma.

Haijing Deng, Anna Kan, Ning Lyu

Pageof 1

Frequent Collaborators

3 joint publications

QiJiong Li

3 joint publications

Ming Shi

2 joint publications

MinKe He

2 joint publications

YeXing Huang